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Abstract
Undifferentiated and dedifferentiated endometrial carcinomas are rare and highly aggressive 
subtypes of uterine cancer, not well characterized at a molecular level. To investigate whether 
dedifferentiated carcinomas carry molecular genetic alterations similar to those of pure 
undifferentiated carcinomas, and to gain insight into the pathogenesis of these tumours, we 
selected a cohort of 18 undifferentiated endometrial carcinomas, 8 of them with a well 
differentiated endometrioid carcinoma component (dedifferentiated endometrioid carcinomas), 
and studied them by immunohistochemistry and massive parallel and Sanger sequencing. Whole 
exome sequencing of the endometrioid and undifferentiated components as well as normal 
myometrium, was also carried out in one case. According to The Cancer Genome Atlas 
classification, we distributed 95% of the undifferentiated carcinomas in this series as follows: a) 
hypermutated tumours with loss of any mismatch repair protein expression and microsatellite 
instability (eight cases, 45%); b) ultramutated carcinomas carrying mutations in the exonuclease 
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domain of POLE (two cases, 11%); c) high copy number alterations (copy-number high) tumours 
group exhibiting only TP53 mutations and high number of alterations detected by FISH (two 
cases, 11%) ; and d) low copy number alterations (copy-number low) tumours with molecular 
alterations typical of endometrioid endometrial carcinomas (five cases, 28%). Two of the latter 
cases, however, also had TP53 mutations and higher number of alterations detected by FISH and 
could have progressed to a copy-number high phenotype. Most dedifferentiated carcinomas 
belonged to the hypermutated group whereas pure undifferentiated carcinomas shared molecular 
genetic alterations with copy-number low or copy-number high tumours. These results indicate 
that undifferentiated and dedifferentiated endometrial carcinomas are molecularly heterogeneous 
tumours, which may have prognostic value.
Introduction
Undifferentiated endometrial carcinoma is a rare but highly aggressive subtype of 
endometrial carcinoma [1], representing approximately 9% of endometrial carcinomas [2]. It 
is often misdiagnosed as grade 3 endometrioid carcinoma. Defining features include: a) 
monotonous medium or large-sized cells; b) diffuse pattern of growth; and c) a lack of 
appreciable glandular, papillary, squamous, or neuroendocrine differentiation [1, 3, 4]. 
Undifferentiated endometrial carcinoma lacks expression of epithelial markers, such as 
keratins, E-cadherin, and mir-200 but express ZEB-1, a well-known repressor of E-cadherin 
[5]. In addition, undifferentiated endometrial carcinoma is frequently associated with 
mismatch repair deficiency [5].
Occasionally, undifferentiated endometrial carcinoma is associated with a low-grade 
endometrioid carcinoma component, hence it is referred to as “dedifferentiated endometrioid 
endometrial carcinoma” [2]. In a recent study [6], a common origin of both components was 
proposed since all driver mutations present in the endometrioid component were also found 
in the undifferentiated (dedifferentiated) component. In that study, most mutations were 
found in genes such as PTEN (40%), PIK3CA (50%), CTNNB1 (30%), and TP53 (30%), 
which are frequently involved in the development of endometrioid carcinomas [6].
However, it is still unclear whether pure undifferentiated carcinomas differ molecularly from 
so-called dedifferentiated carcinomas.
Recently, The Cancer Genome Atlas (TCGA) Research Network reported an integrated 
molecular analysis of 373 endometrial carcinomas which were evaluated at the genomic, 
exomic, transcriptomic, epigenomic, and protein levels. This analysis showed that 
endometrioid and serous carcinomas can be classified into four distinct molecular 
categories: hypermutated microsatellite unstable, POLE ultramutated, copy-number low/
microsatellite stable and copy-number high/”serous-like”. The hypermutated, ultramutated 
and copy-number low subgroups were represented predominantly by endometrioid tumours 
whereas the copy-number high/”serous-like” subgroup was composed of both serous and 
high-grade endometrioid subtypes. Mixed endometrial carcinomas were assigned to the 
copy-number low (endometrioid) and the copy-number high (“serous-like”) tumours, 
indicating the molecular genetic diversity of these neoplasms. However, no mixed 
undifferentiated/well differentiated (dedifferentiated) carcinomas were included in the 
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TCGA study. Finally, a less sophisticated and practical way of assigning endometrial 
carcinomas to the TCGA categories, based on immunohistochemical analysis of mismatch 
repair proteins and TP53 and POLE mutational analyses, has been proposed [7].
In the current study, we investigated whether undifferentiated and dedifferentiated 
carcinomas share molecular genetic alterations and or they represent a molecularly 
homogenous group of tumours. To this end, we selected a cohort of 18 undifferentiated 
endometrial carcinomas, eight of them with an endometrioid carcinoma component, to be 
massively sequenced using Haloplex Cancer Research Panel enrichment kit and Ion Torrent 
sequencing platform. In addition, one case was subjected to whole exome sequencing for 
comparing the genetic alterations of the endometrioid and the undifferentiated elements.
Materials and Methods
Case selection
This study includes a total of 22 endometrial carcinomas, diagnosed initially as 
undifferentiated carcinomas, from the files of the Departments of Pathology of Hospital 
Universitario Ramón y Cajal, Madrid; Massachusetts General Hospital, Boston; Memorial 
Sloan Kettering Cancer Center, New York; Hospital de la Santa Creu i Sant Pau, Barcelona; 
and Hospital Universitari Arnau de Vilanova, Lleida). Clinicopathological features are 
presented in Suppl. Table 1. The pathological and immunohistochemical features of 10 cases 
have been previously reported in part [5]. The diagnosis of undifferentiated carcinoma was 
based not only on conventional morphological features but also on the characteristic 
immunohistochemical pattern reported previously; i.e., absence of E-cadherin expression 
together with ZEB1 nuclear immunoreaction (see Figures 1 and 2) [8]. Two of the 22 
tumours were reclassified as grade 3 endometrioid carcinomas containing areas of well-
differentiated carcinoma. In these two cases, the solid component, interpreted initially as 
undifferentiated carcinoma, expressed membranous E-cadherin and lacked the nuclear ZEB1 
immunoreaction. Two other cases were reclassified as carcinosarcomas with areas of 
undifferentiated carcinoma. The study was approved by the Institutional Review Board of 
the Hospital Ramón y Cajal and by the other participating medical institutions.
Immuhistochemistry
The following antibodies were used: E-cadherin (cat #IR059; DAKO, Glostrup, Denmark; 
ready to use) and ZEB1 (cat #ab87280; abcam, Cambridge, UK; dilution 1:300), p53: (cat 
#IR616; DAKO, Glostrup, Denmark; ready to use), MLH1 (cat #M3640; DAKO, Glostrup, 
Denmark; ready to use), PMS2 (cat #IR087; DAKO, Glostrup, Denmark; ready to use), 
MSH2 (cat #M3639; DAKO, Glostrup, Denmark; ready to use), MSH6 (cat #M3646; 
DAKO, Glostrup, Denmark; ready to use), β-catenina (cat #0001109QD; Master 
Diagnóstica, Granada, Spain; ready to use), ARID1A (cat #HPA005456; Sigma, St Louis, 
USA; dilution 1:500) and SMARCB1 (BD Biosciences, Franklin Lakes, NJ USA; dilution: 
1/100). Immunostaining was performed using the EnVision detection system (K5007, 
Dako).
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Haloplex Cancer Research Panel was used as enrichment kit. This panel targeted 1205 
hotspots in 199 regions from 47 genes, including most frequently mutated genes in 
endometrioid endometrial carcinoma (PTEN, PIK3CA, PIK3R1, KRAS, CTNNB1, FGFR2 
or TP53), with the exception of ARID1A. In order to know whether targeted regions 
overlapped with mutations found in TCGA study [9], we calculated the percentage of 
variants located across covered regions and across hotspot regions plus/minus 30 bp. 
Sequencing of libraries was performed on Ion Torrent sequencing platform in four chips 
class 316 following standard procedures, expecting an average of 25 Mb per sample (around 
17 Mb per sample were recommended by Haloplex Protocol).
To analyze sequencing results and to avoid an unacceptable false negative rate, a 
bioinformatics analysis pipeline was developed using TMAP (https://github.com/
iontorrent/TS/tree/master/Analysis/TMAP) as aligner and VarScan [10] as variant-caller, 
with no filters. Variant annotation was performed using the VEP from Ensembl with version 
74 of the human reference genome (http://www.ensembl.org/info/docs/tools/vep/
index.html). Variants were then filtered using the functional information (selecting only 
deleterious variants), the variant allele frequency (> 0.15) and the strand-bias from both the 
variant and the reference allele. In the case of having normal tissue available, those variants 
present in the normal component were ruled out. Taking into account the information from 
Sanger sequencing, visual inspection of variants was performed using IGV browser [11] as 
the final selection step.
FISH analyses
In 11 tumours, interphase fluorescence in situ hybridization (FISH) analysis was performed 
using commercial probes delineating several loci on different chromosomal regions (see 
Supp. Table 2). In dedifferentiated tumours, FISH analysis was limited to the 
undifferentiated component. Pre-treatment of slides, hybridization, post-hybridization 
processing, and signal detection were performed as reported elsewhere [12]. Only samples 
showing sufficient FISH efficiency (> 90% nuclei with signals) were evaluated. Signals were 
scored in at least 50 no overlapping, intact nuclei. Non-neoplastic cells present in the section 
were used as a control. Results were interpreted as follows: a) gain: when the ratio between 
gene and control probe signals was between 1 and 2.5 (both excluded); b) amplification: 
when the ratio between gene and control probe signals was ≥ 2.5; c) deletion: when the ratio 
between gene and control probe signals was < 1; d) aneuploidy: the presence of only one 
gene and centromeric probes in more than 50% of cells evaluated was considered monosomy 
while presence of ≥ 3 gene and centromeric probes was considered polisomy. For EGFR 
gene evaluation the presence of three and four centromeric probes was considered trisomy 
and tetrasomy respectively and the presence of ≥ 5 centromeric and gene probes was 
considered polisomy.
Whole exome analysis
To find out whether or not the mutational profile of the undifferentiated component of the 
mixed carcinomas differed from that of the differentiated component within an individual 
tumour, we performed whole exome sequencing of both components, together with normal 
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myometrial tissue (UEC-14), following technical specifications from Sistemas Genómicos 
S.L., on an Illumina Hiseq 2000 platform. The enrichment method was Agilent SureSelect 
Exome V4, targeting a total of 51 Mb. Bioinformatics analysis was performed as described 
above, with the exception of using Novoalign (http://www.novocraft.com/products/
novoalign/) instead of TMAP in the alignment step. Somatic mutations were considered 
those present in the tumour but not in normal tissue. CONTRA package [13] was used to 
analyse the genome instability using the normal component data as control.
Sanger sequencing
To validate massive parallel sequencing data, primers were designed to target different 
mutations in PIK3CA, PIK3R1, ATM, and SMARCB1 (Supp. Table 3). Since Haloplex 
Cancer Research Panel lacks coverage of some PTEN mutations, we also designed 12 
primer-pairs (Supp. Table 3) to amplify the nine PTEN’s exons by PCR and perform Sanger 
sequencing for all cases. To further classify tumours within the TCGA ultramutated group 
[9], we designed two pairs of primers (Supp. Table 3) to sequence the two usually mutated 
exons (Exon 9 and Exon 13) containing the protein catalytic domain of POLE in all cases.
Results
Pathological and immunohistochemical features
Of the 18 undifferentiated endometrial carcinomas, seven were pure and the remaining 11 
cases exhibited an endometrioid component (a grade 1–2 endometrioid carcinoma in 10, and 
a grade 3 endometrioid carcinoma in 1).
The most relevant clinical, pathological, inmunohistochemical, and molecular genetic 
features of all 22 tumours are presented in Supp. Table 4. Here we describe the 
immunohistochemical and molecular features of the 18 undifferentiated/dedifferentiated 
endometrial carcinomas.
Every immunohistochemical essay was performed in the 7 pure undifferentiated cases, in the 
undifferentiated component of the 11 dedifferentiated cases and in the differentiated 
component of 7 dedifferentiated cases. In the differentiated component of 4 dedifferentiated 
cases, IHQ essays were not possible to perform due to the lack of dedifferentiated tissue in 
the preparations under study.
Diagnosis for undifferentiated status was confirmed as stated in material and methods: 
undifferentiated component showed lack of E-cadherin staining and nuclear staining of 
ZEB1 whereas differentiated component showed normal membrane staining of E-cadherin 
and absence of ZEB1 staining. Only in case UEC-5 this pattern was not confirmed due to the 
lack of material.
Loss of ARID1A expression was observed in 10 out of the 18 cases (56 %); being the loss 
total in eight and focal in two cases respectively. Noteworthy, the two cases with focal loss 
were dedifferentiated carcinomas and the loss of expression was limited almost exclusively 
to the undifferentiated component (in one case, a few areas of the differentiated 
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endometrioid component had loss of ARID1A expression, see Supp. Figure 1). Both cases 
also exhibited loss of MLH1/PMS2 expression across the entire tumour.
Loss of expression of at least one mismatch repair protein was found in eight tumours 
(45%); six showed loss of MLH1/PMS2, one loss of PMS2 only, and one loss of MSH2/
MSH6.
p53 overexpression (at least in 75% of tumour cells) was found in three cases (17%). 
Noteworthy, in the dedifferentiated carcinoma, p53 overexpression was restricted only to the 
undifferentiated component.
Nuclear β-catenin immunoreaction was seen only in one case (6%) and was also confined to 
the undifferentiated component of a dedifferentiated carcinoma (Supp. Figure 2).
All tumours were checked for SMARCB1 (INI1, BAF47) expression by 
immunohistochemistry. Normal nuclear SMARCB1 staining was found in all cases.
Mutation analysis
We first compared the mutations covered by Haloplex Cancer Panel in PTEN, PIK3CA, 
PIK3R1, KRAS, CTNNB1, FGFR2, and TP53 with those previously reported for 
endometrioid endometrial carcinomas, mainly by TCGA [9]. We found coverage greater 
than 90% for all genes except for PTEN in which coverage reached 50% only. (Supp. Table 
5). Accordingly, we performed Sanger sequencing for all 9 PTEN exons.
For the 16 undifferentiated endometrial carcinomas subjected to massive parallel sequencing 
(Supp. Table 6), the mean number of bases obtained per sample was 25,711,256, which 
allowed a median depth per sample of 40. However, the distribution of the depth was not 
homogeneous along the target regions and most of the depth was limited to the hotspot 
regions (median depth per sample of 236). We observed that was due to the fact that larger 
amplicons could not be sequenced in most of the FFPE samples as several regions were not 
covered at all since designed amplicons of suitable-size were not available for Ion Torrent 
protocol (data not shown).
Taking into account Haloplex and Sanger sequencing results, a total of 43 different 
pathogenic mutations were identified in the set of 16 undifferentiated carcinomas (Supp. 
Table 4). Ten out of 43 (23%) mutations were found in PTEN, and four of them were only 
detected by Sanger sequencing. Mutations were also detected in other genes commonly 
mutated in different types of endometrial carcinomas, such as TP53 (4 out of 43, 9%), 
PIK3R1 (3 out of 43, 7%) and PIK3CA (3 out of 43, 7%), KRAS (2 out of 43, 5%) and 
CTNNB1 (1 out of 43, 2%) (Supp. Table 4). POLE mutational study showed that two 
tumours carried variants previously described as pathogenic and associated with 
ultramutated phenotype (Supp. Table 4) [9, 14–16].
Regarding phenotype-genotype correlations, only one pure undifferentiated carcinoma had 
mismatch repair deficiency in contrast to seven out of 11 dedifferentiated tumours. The other 
six pure undifferentiated carcinomas carried PTEN or TP53 mutations as their main 
molecular alterations (Figure 3).
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Chromosomal alteration detected by FISH
A total of seven chromosomes and 11 genes were checked for alterations in 11 cases (six 
pure undifferentiated and five dedifferentiated cases) (Supp. Table 7). Pure undifferentiated 
cases with TP53 mutations showed higher number of alterations (5.75 in average) compared 
to TP53 wild type cases (1 in average), which is consistent with previous results [9]. 
Noteworthy, one case with no identified molecular alteration showed the highest number of 
aberrations (3) among TP53 wild type cases.
TCGA based molecular classification of undifferentiated/dedifferentiated carcinomas
According to the molecular classification scheme proposed by TCGA and following the 
simplified approach proposed in a recent study [7], we classified 17 out of the18 
undifferentiated carcinomas in this series as follows: eight cases (45%) showing loss of any 
mismatch repair protein expression into the microsatellite instability hypermutated category; 
two cases (11%) carrying pathogenic mutations in the exonuclease domain of POLE into the 
ultramutated group; two cases (11%) showing only TP53 mutations and high number of 
alterations detected by FISH into the copy-number high group; and five cases (28%) with 
molecular alterations typical of copy-number low endometrioid endometrial carcinomas. 
However, two of the latter cases showed additional mutations in TP53 and higher number of 
alterations detected by FISH; therefore, these tumours could have progressed to a copy-
number high phenotype (Figure 3B). In the remaining case, different chromosomal 
alterations were identified by FISH but no molecular alteration that allowed its classification 
was found.
Exome sequencing
Whole exome sequencing allowed the identification of somatic variants across most exonic 
regions in the genome of UEC-14. The final median depth across target regions was 38, 33 
and 36 with 0.20%, 0.17% and 0.25% of regions not covered at all (>90% of bases not 
covered for at least one read) for normal tissue, endometrioid, and undifferentiated 
carcinoma samples respectively. A total of 123 somatic variants (40 indels and 83 
substitutions) were identified for both tumour components (see genes affected in Supp. Table 
8). In addition, 44 somatic variants (19 indels and 25 substitutions) were identified only in 
the undifferentiated component, and three somatic variants (two indels and one substitution) 
were exclusively found in the endometrioid component. Mutations identified by massive 
parallel sequencing were also identified by whole exome sequencing. In agreement with the 
loss of expression of ARID1A in this case, two pathogenic mutations (Y1233* and 788delC) 
were detected in both endometrioid and undifferentiated components.
Genome instability study (see Figure 1K) showed a flat pattern for the differentiated 
component with no apparent alteration, whereas the pattern for the dedifferentiated 
component (see Figure 1K) showed trisomy of chromosome 8, partial loss of 1p36.33 and 
uncertain monosomy of chromosomes 15 and 16. Chromosome 8 trisomy was confirmed by 
FISH (see Figure 1J).
UEC-14 showed rhabdoid features in the undifferentiated component. Since we found a 
heterozygous deleterious mutation in SMARCB1 gene, we analysed all 18 tumours for 
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SMARCB1 (INI1, BAF47) expression by immunohistochemistry. As stated before, normal 
nuclear SMARCB1 expression was found in all cases.
Discussion
The results of this study suggest that undifferentiated carcinomas may develop through any 
of the four molecular pathways described by TCGA for endometrial carcinomas; i.e., 
hypermutated (mismatch repair deficiency), ultramutated (POLE mutated), copy-number 
low, and copy-number high (TP53 mutated) [9]. Nearly half (45%) of the undifferentiated 
carcinomas in this series belong to the hypermutated group, which contrasts with the 
frequency of microsatellite instability reported in most series of sporadic endometrial cancer 
(15%–30%) [17]. However, the frequency of mismatch repair deficiency seems to be higher 
in high-grade endometrioid carcinomas (45%–63%) [5, 18] suggesting an intrinsic potential 
for tumour progression of carcinomas from the hypermutated group.
A remarkable finding in this study was that two undifferentiated carcinomas carried POLE 
mutations that affect the activity of the catalytic subunit, involved in nuclear DNA 
replication and repair as described by TCGA [9, 14, 15]. Endometrioid carcinomas with 
POLE exonuclease domain mutations have been recently described to be frequently of high 
histologic grade exhibiting morphologic heterogeneity and ambiguity, and tumour-
infiltrating lymphocytes and/or peri-tumour lymphocytes. [19]. One of the two ultramutated 
tumours in this series was a dedifferentiated carcinoma rich in tumour-infiltrating 
lymphocytes and the other was a pure undifferentiated carcinoma. The former tumour also 
had a TP53 mutation confined to the undifferentiated component (Figure 2) similarly to the 
TCGA ultramutated carcinomas. A dedifferentiated carcinoma carrying POLE exonuclease 
domain mutations has recently been reported [16]. In this case, aberrant p53 
immunoreaction was also confined to the undifferentiated component.
One third of undifferentiated carcinomas in our series derive from copy-number low 
endometrial carcinomas. In this group, the most frequent driver alteration was PTEN 
mutation, often associated with mutations in other genes of the same pathway (PIK3CA, 
PIK3R1), in endometrioid endometrial carcinomas [9]. However, two cases (11%) that 
lacked the characteristic molecular genetic alterations of endometrioid carcinomas, had 
TP53 mutations, suggesting that at least some undifferentiated carcinomas might develop 
through the “serous-like” (copy-number high) pathway.
Regarding genotype-phenotype correlation and based on a relatively small number of cases, 
this study suggests that dedifferentiated carcinomas occur mainly in the setting of 
endometrioid carcinomas with microsatellite instability or POLE mutations, whereas most 
pure undifferentiated carcinomas develop from the copy-number low or “serous-like” copy-
number high tumours.
Another purpose of this study was to investigate the molecular mechanisms that allow 
“dedifferentiation” of endometrioid carcinomas to undifferentiated carcinomas. The role of 
CTNNB1, PPP2R1A, and TP53 in this phenomenon has been suggested by a previous report 
[6]; however, that report lacked information regarding mismatch repair proteins, ARID1A 
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expression, and POLE mutation analysis. Our results suggest that different pathways may be 
followed depending on the molecular subtype (Figure 3). Thus, tumours with mismatch 
repair deficiency (hypermutated) seem to acquire a dedifferentiated phenotype through 
accumulation of mutations in genes that are regularly altered in endometrioid carcinomas 
and not TP53 mutations. Furthermore, our results suggest that ARID1A plays a role in the 
progression of endometrial carcinomas with mismatch repair deficiency [20]. We found that 
70% of tumours with loss of ARID1A had microsatellite instability and that loss of ARID1A 
occurred mainly in the undifferentiated component of two dedifferentiated carcinomas with 
mismatch repair deficiency in both components. [21]. Similarly, in the case of one 
dedifferentiated carcinoma with microsatellite instability, we found CTNNB1 mutations 
exclusively in the undifferentiated component (Supp. Table 4).
On the other hand, tumours with PTEN mutations as main driver (copy-number low 
carcinomas) probably might acquire undifferentiated phenotype through mutations in TP53, 
as such mutations were encountered in 2 out of 5 cases with PTEN mutations lacking 
mismatch repair deficiency or POLE mutations.
In our series, the ultramutated tumours seemed to have progressed to undifferentiated 
carcinomas by accumulating mutations in genes involved in the development of 
endometrioid carcinomas and/or TP53 mutations. The dedifferentiated tumour with POLE 
mutation showed loss of ARID1A in both components but p53 overexpression and TP53 
mutation were found exclusively in the poorly differentiated/undifferentiated elements [16]. 
In contrast, the pure undifferentiated tumour had ARID1A loss and PTEN mutations. Our 
results are consistent with those of the TCGA which reported mutations in PTEN (94%), 
FBXW7 (82%), ARID1A (76%), PIK3CA (71%), and TP53 (35%) in the POLE-mutated 
tumours [19]. Regarding prognosis, although the size of our series is not large enough to 
extract conclusions, we observed that the 4 patients classified as copy-number high or copy-
number low to copy-number high had deceased whereas the two patients classified as copy-
number low were alive at the time of this study (no data was available for the third patient 
classified as copy-number low).
In our series, the study of the complete exome in one dedifferentiated carcinoma with 
rhabdoid-like features revealed the presence of a heterozygous mutation in SMARCB1 
limited to the undifferentiated component. This led us to analyze SMARCB1 (INI1) 
expression in the entire series; however, no tumour showed loss of SMARCB1expression. 
Thus, it appears that inactivation of one copy of SMARCB1 is not enough for the 
development of rhabdoid features in undifferentiated carcinomas. However, other studies 
have demonstrated that expression of SMARCB1 and more frequently of SMARCA4 can be 
lost in the undifferentiated component of dedifferentiated carcinomas [22, 23]. These 
findings, together with our observation of frequent ARID1A loss, suggest a role of 
SWI/SNF complex alterations in the pathogenesis of an undifferentiated phenotype in 
endometrial carcinomas.
In summary, this study shows that undifferentiated endometrial carcinomas may share 
molecular genetic alterations with any of the four molecular subgroups of endometrial 
cancer described by TCGA. Most undifferentiated carcinomas with a differentiated 
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component (dedifferentiated carcinomas) occurred in the setting of mismatch repair 
deficiency (hypermutated tumours) with accumulation of molecular genetic alterations 
characteristic of endometrioid carcinomas, such as ARID1A, PIK3CA or CTNNB1 
mutations in the undifferentiated component. TP53 mutation may act as the initial driver for 
some undifferentiated carcinomas developing through a “serous-like” pathway or it may be 
involved in the progression of endometrioid tumours without microsatellite instability but 
exhibiting PTEN mutations. Lastly, undifferentiated carcinomas carrying POLE mutations 
can evolve through endometrioid and/or “serous-like” pathways.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Molecular characteristics of UEC-14, a dedifferentiated endometrioid carcinoma with 
mismatch repair and ARID1A deficiency. A) Hematoxylin-Eosin staining showing a well-
differentiated component besides an undifferentiated component. Magnified image showed 
the rhabdoid features of the undifferentiated component. B) E-cadherin staining positive for 
differentiated component, negative for undifferentiated component. C) ZEB-1 staining 
positive for undifferentiated component, negative for differentiated component. D) Negative 
MLH-1 staining. E) Negative ARID1A staining. F) Positive SMARCB1 staining. G) Wild-
type SMARCB1 (chr22:24134051-24134059) sequence obtained for UEC-14 normal 
component. H) Wild-type SMARCB1 sequence obtained for UEC-14 endometrioid 
component. I) SMARCB1 variant (chr22:24134057 A->T) found in UEC-14 
undifferentiated component identified by exome sequencing. Observed low variant allele 
frequency agreed with NGS results (~18%). I) Confirmation of chr8 trisomy constrained to 
undifferentiated component by FISH using a chr8-centromere probe.
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Molecular characteristics of UEC-13, a dedifferentiated endometrioid carcinoma with POLE 
and TP53 mutations. A) Hematoxylin-Eosin staining showing a well-differentiated 
component beside undifferentiated component. B) Hematoxylin-Eosin staining showing a 
field within the undifferentiated component with two glands (yellow arrows). C) Progressive 
loss of E-cadherin expression throughout undifferentiated component. D) Focal gain of 
ZEB-1 expression throughout undifferentiated component. E) TP53 staining positive for 
undifferentiated component, negative for differentiated component. F) 
Chr12:133253143-133253160 sequence. From up to bottom: wild-type sequence, POLE 
S297F mutation identified in UEC-13 undifferentiated component and POLE S297F 
mutation identified in UEC-13 endometrioid component.
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A) Summary of the molecular characteristics observed in dedifferentiated, pure 
undifferentiated (I) and high-grade endometrioid carcinomas (II); and carcinosarcomas (III). 
Alteration for a gene (mutation or loss of expression) is indicated in red, no identified 
alteration for a gene (wild-type sequence or regular expression) in white and gene-not-
analyzed for a sample in grey. B) Schematic classification of the 18 undifferentiated/
dedifferentiated tumours in this series according to TCGA molecular classification.
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